Description: biOasis Technologies Inc. is a development-stage biopharmaceutical company, which is focused on research, development and commercialization of technologies and products that are intended for the treatment of central nervous system (CNS) diseases and diseases of the brain. The Company researches and develops products for diagnosis and treatment of neurological diseases and disorders. It is engaged in the development of its vectors Transcend and Transcendpep for the transport of therapeutic agents across the blood brain barrier (BBB). The Transcend brain delivery platform exploits the BBB penetrating properties of a recombinant soluble human protein known as melanotransferrin (MTf or p97) and portions thereof. Transcend delivery molecules have the ability to transport a range of molecules across the BBB. The Company owns approximately 30 the United States and foreign patents/applications related to p97 as a BBB delivery vector and as a biomarker for Alzheimer's disease.
Home Page: www.bioasis.us
BTI Technical Analysis
157 Church Street
New Haven,
CT
06510
United States
Phone:
203 533 7082
Officers
| Name | Title |
|---|---|
| Dr. Deborah Ann Rathjen B.Sc. (Hons.), FTSE, M.A.I.C.D., Ph.D., Q.C. | Exec. Chairman, CEO & Pres |
| Mr. Dave Jenkins | Chief Financial Officer |
| Mr. Graeme Dick | Director of Investor Relations |
| Mr. Kim Elton | Director of Marketing |
| Mr. Doug Williams MBA | Exec. VP & Chief Bus. Officer |
| Dr. Mei Mei Tian | VP & Head of External Research |
Exchange: V
Country: CA : Canada
Currency: Canadian Dollar (C$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 54.0377 |
| Price-to-Sales TTM: | 35.1467 |
| IPO Date: | |
| Fiscal Year End: | February |
| Full Time Employees: | 0 |